Walter T. Hughes, MD
Without treatment, Pneumocystis carinii pneumonia is almost always fatal in the immunocompromised host. Two drugs, trimethoprim-sulfamethoxazole and pentamidine isethionate, are currently the only drugs approved by the Food and Drug Administration (FDA) for the treatment of this infection. The drugs are equally effective and achieve therapeutic success in at least 75% of cases. Although these two drugs are important in the treatment of P. carinii pneumonia, they fall short as ideal therapeutic agents. More than 50% of patients with the acquired immunodeficiency syndrome (AIDS) have adverse reactions to either of the drugs (1). Also, neither drug eradicates P. carinii, exerting
Hughes WT. A New Drug (566C80) for the Treatment of Pneumocystis carinii Pneumonia. Ann Intern Med. ;116:953–954. doi: 10.7326/0003-4819-116-11-953
Download citation file:
Published: Ann Intern Med. 1992;116(11):953-954.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use